KMT2A-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for KMT2A-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new KMT2A-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for KMT2A-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo tackles tough leukemia
Disease control Not yet recruitingThis early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand si…
Matched conditions: KMT2A-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New combo aims to wipe out stubborn leukemia cells
Disease control Not yet recruitingThis study looks at adding a new drug, revumenib, to standard treatment for people with a specific genetic type of leukemia (KMT2A-translocation) that still has traces of disease after initial therapy. About 90 adults and children will be randomly assigned to get either the usual…
Matched conditions: KMT2A-REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC